Treatment, outcome, and cost of care in children with idiopathic thrombocytopenic purpura

Manjusha Kumar, Terry Vik, Cynthia S. Johnson, M. Elaine Southwood, James Croop

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

Data were reviewed on treatment patterns, outcome, and hospital charges for children with idiopathic thrombocytopenic purpura (ITP). Records of 186 children with ITP, seen between January 1997 and April 2001, were reviewed. Hospital charges for initial management and first re-treatment were calculated by combining physician, hospital, and pathology charges. Anti-D immune globulin [anti-D IG] was used in 32.3%, intravenous immune globulin [IVIG] in 22.6%, steroids in 22.6%, combination therapies in 8%, and 14.5% were observed. Two patients had CNS bleeding, one with intraventricular hemorrhage at diagnosis, and the other with a parietal bleed 1 year from diagnosis. There was no significant differences in time to reach platelet counts of 20, 50, or 150 (x109/L) across different treatment groups. There was no significant difference in median charges for the IVIG and anti-D IG groups for the initial treatment of ITP. However, the IVIG was significantly more expensive than steroids or observation. Charges for the anti-D IG group were higher than the observation group but not the steroid group. After drug charges were excluded, patients in the IVIG group had statistically higher charges compared to patients in anti-D IG group. Almost half the patients were re-treated. There was no significant difference between anti-D IG, IVIG, and steroid groups when initial and re-treatment charges were combined. The observation group remained least expensive. Outcome for children with ITP is similar regardless of initial management. There is not a statistically significant difference in hospital charges between patients treated with anti-D IG and IVIG. The IVIG-treated group tends to be more costly, but this is not due to drug charges. Re-treatment is common and decreases the difference in patient charges among initial therapies.

Original languageEnglish
Pages (from-to)181-187
Number of pages7
JournalAmerican Journal of Hematology
Volume78
Issue number3
DOIs
StatePublished - Mar 2005

Fingerprint

Idiopathic Thrombocytopenic Purpura
Intravenous Immunoglobulins
Child Care
Health Care Costs
Hospital Charges
Immunoglobulins
Steroids
Observation
Therapeutics
Hemorrhage
Platelet Count
Pharmaceutical Preparations
RHO(D) antibody
Pathology
Physicians

Keywords

  • Bleeding
  • Cost
  • Immune globulin
  • Platelet
  • Steroids

ASJC Scopus subject areas

  • Hematology

Cite this

Treatment, outcome, and cost of care in children with idiopathic thrombocytopenic purpura. / Kumar, Manjusha; Vik, Terry; Johnson, Cynthia S.; Southwood, M. Elaine; Croop, James.

In: American Journal of Hematology, Vol. 78, No. 3, 03.2005, p. 181-187.

Research output: Contribution to journalArticle

Kumar, Manjusha ; Vik, Terry ; Johnson, Cynthia S. ; Southwood, M. Elaine ; Croop, James. / Treatment, outcome, and cost of care in children with idiopathic thrombocytopenic purpura. In: American Journal of Hematology. 2005 ; Vol. 78, No. 3. pp. 181-187.
@article{b5bb5e7fab644f27a2c8d18bfbb090b3,
title = "Treatment, outcome, and cost of care in children with idiopathic thrombocytopenic purpura",
abstract = "Data were reviewed on treatment patterns, outcome, and hospital charges for children with idiopathic thrombocytopenic purpura (ITP). Records of 186 children with ITP, seen between January 1997 and April 2001, were reviewed. Hospital charges for initial management and first re-treatment were calculated by combining physician, hospital, and pathology charges. Anti-D immune globulin [anti-D IG] was used in 32.3{\%}, intravenous immune globulin [IVIG] in 22.6{\%}, steroids in 22.6{\%}, combination therapies in 8{\%}, and 14.5{\%} were observed. Two patients had CNS bleeding, one with intraventricular hemorrhage at diagnosis, and the other with a parietal bleed 1 year from diagnosis. There was no significant differences in time to reach platelet counts of 20, 50, or 150 (x109/L) across different treatment groups. There was no significant difference in median charges for the IVIG and anti-D IG groups for the initial treatment of ITP. However, the IVIG was significantly more expensive than steroids or observation. Charges for the anti-D IG group were higher than the observation group but not the steroid group. After drug charges were excluded, patients in the IVIG group had statistically higher charges compared to patients in anti-D IG group. Almost half the patients were re-treated. There was no significant difference between anti-D IG, IVIG, and steroid groups when initial and re-treatment charges were combined. The observation group remained least expensive. Outcome for children with ITP is similar regardless of initial management. There is not a statistically significant difference in hospital charges between patients treated with anti-D IG and IVIG. The IVIG-treated group tends to be more costly, but this is not due to drug charges. Re-treatment is common and decreases the difference in patient charges among initial therapies.",
keywords = "Bleeding, Cost, Immune globulin, Platelet, Steroids",
author = "Manjusha Kumar and Terry Vik and Johnson, {Cynthia S.} and Southwood, {M. Elaine} and James Croop",
year = "2005",
month = "3",
doi = "10.1002/ajh.20295",
language = "English",
volume = "78",
pages = "181--187",
journal = "American Journal of Hematology",
issn = "0361-8609",
publisher = "Wiley-Liss Inc.",
number = "3",

}

TY - JOUR

T1 - Treatment, outcome, and cost of care in children with idiopathic thrombocytopenic purpura

AU - Kumar, Manjusha

AU - Vik, Terry

AU - Johnson, Cynthia S.

AU - Southwood, M. Elaine

AU - Croop, James

PY - 2005/3

Y1 - 2005/3

N2 - Data were reviewed on treatment patterns, outcome, and hospital charges for children with idiopathic thrombocytopenic purpura (ITP). Records of 186 children with ITP, seen between January 1997 and April 2001, were reviewed. Hospital charges for initial management and first re-treatment were calculated by combining physician, hospital, and pathology charges. Anti-D immune globulin [anti-D IG] was used in 32.3%, intravenous immune globulin [IVIG] in 22.6%, steroids in 22.6%, combination therapies in 8%, and 14.5% were observed. Two patients had CNS bleeding, one with intraventricular hemorrhage at diagnosis, and the other with a parietal bleed 1 year from diagnosis. There was no significant differences in time to reach platelet counts of 20, 50, or 150 (x109/L) across different treatment groups. There was no significant difference in median charges for the IVIG and anti-D IG groups for the initial treatment of ITP. However, the IVIG was significantly more expensive than steroids or observation. Charges for the anti-D IG group were higher than the observation group but not the steroid group. After drug charges were excluded, patients in the IVIG group had statistically higher charges compared to patients in anti-D IG group. Almost half the patients were re-treated. There was no significant difference between anti-D IG, IVIG, and steroid groups when initial and re-treatment charges were combined. The observation group remained least expensive. Outcome for children with ITP is similar regardless of initial management. There is not a statistically significant difference in hospital charges between patients treated with anti-D IG and IVIG. The IVIG-treated group tends to be more costly, but this is not due to drug charges. Re-treatment is common and decreases the difference in patient charges among initial therapies.

AB - Data were reviewed on treatment patterns, outcome, and hospital charges for children with idiopathic thrombocytopenic purpura (ITP). Records of 186 children with ITP, seen between January 1997 and April 2001, were reviewed. Hospital charges for initial management and first re-treatment were calculated by combining physician, hospital, and pathology charges. Anti-D immune globulin [anti-D IG] was used in 32.3%, intravenous immune globulin [IVIG] in 22.6%, steroids in 22.6%, combination therapies in 8%, and 14.5% were observed. Two patients had CNS bleeding, one with intraventricular hemorrhage at diagnosis, and the other with a parietal bleed 1 year from diagnosis. There was no significant differences in time to reach platelet counts of 20, 50, or 150 (x109/L) across different treatment groups. There was no significant difference in median charges for the IVIG and anti-D IG groups for the initial treatment of ITP. However, the IVIG was significantly more expensive than steroids or observation. Charges for the anti-D IG group were higher than the observation group but not the steroid group. After drug charges were excluded, patients in the IVIG group had statistically higher charges compared to patients in anti-D IG group. Almost half the patients were re-treated. There was no significant difference between anti-D IG, IVIG, and steroid groups when initial and re-treatment charges were combined. The observation group remained least expensive. Outcome for children with ITP is similar regardless of initial management. There is not a statistically significant difference in hospital charges between patients treated with anti-D IG and IVIG. The IVIG-treated group tends to be more costly, but this is not due to drug charges. Re-treatment is common and decreases the difference in patient charges among initial therapies.

KW - Bleeding

KW - Cost

KW - Immune globulin

KW - Platelet

KW - Steroids

UR - http://www.scopus.com/inward/record.url?scp=14644389349&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=14644389349&partnerID=8YFLogxK

U2 - 10.1002/ajh.20295

DO - 10.1002/ajh.20295

M3 - Article

VL - 78

SP - 181

EP - 187

JO - American Journal of Hematology

JF - American Journal of Hematology

SN - 0361-8609

IS - 3

ER -